In another analysis of the SELECT study recently published in Nature Medicine , Dr
New Phase 3 data reported by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a partner of Regeneron Pharmaceuticals, show that the investigational GLP-1/GIP dual agonist olatorepatide achieved up to 19.3% mean weight loss at Week 48 in adults with obesity
Semaglutide GLP-1 works by mimicking a natural hormone in your body that helps regulate appetite and blood sugar levels, but the process takes time
Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied
Semaglutide (Wegovy) In the pivotal STEP-1 trial, semaglutide 2.4 mg produced ~14.9% total body weight loss , significantly greater than placebo5